Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The company plans to offer 2.8 million shares priced between $8 and $10 per share, with a proposed listing on the New York Stock Exchange under the ticker "EOHC."

Edison Oncology specializes in developing small-molecule oncology drug candidates through formulation optimization, drug repurposing, and next-generation mechanism research. Its pipeline includes Phase 1-2a assets targeting ARID1A-mutated cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company advances its programs via traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.

Financial reports indicate the company generated $446,000 in revenue over the 12-month period ending September 30, 2025.